PALVELLA THERAPEUTICS, INC. (PVLA)
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Palvella Therapeutics, Inc.
NASDAQ:PVLAHealthcare · Biotechnology
-3.58%$146.15
AH$148.00+1.27%vs close
Mkt Cap$2.11B
Float11.08M
O/S14.41M
Vol
$ Vol
RVOL
Inst Own97.9%
SI21.7%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$41.72M
Total Assets$59.56M
Free Cash Flow-$25.01M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$633K
Total Equity$27.98M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PVLA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$59.56M
Liabilities$31.58M
Accounts Receivable$0
Accounts Payable$4.59M
Inventory$0
PP&E (Net)$572K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $0 | $0 | $25.9M | $31.42M |
| YoY Growth | - | - | - | -17.6% | - |
| Cost of Revenue | $0 | $0 | $0 | $2.78M | $2.37M |
| Gross Profit | $0 | $0 | $0 | $23.12M | $29.05M |
| Gross Margin | - | - | - | 89.3% | 92.5% |
| Research and Development | $22.84M | $8.15M | $8.79M | $50.21M | $64.2M |
| Selling, General, and Administrative | $15.76M | $5.94M | $3.08M | $16.38M | $16.68M |
| Other | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $38.6M | $14.1M | $11.87M | $66.6M | $80.88M |
| Operating Income (EBIT) | -$38.6M | -$14.1M | -$11.87M | -$43.47M | -$51.83M |
| Operating Margin | - | - | - | -167.8% | -165.0% |
| Interest Expense | $5.82M | $4.32M | $0 | $0 | $0 |
| Interest Income | $2.59M | $642K | $6.26M | $721K | $4K |
| Other Income (Expense) | -$3.11M | -$3.34M | $30.56M | $10.2M | $6.09M |
| Income Before Tax (EBT) | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M |
| Net Income Margin | - | - | - | -128.5% | -145.6% |
| Supplementary Data | |||||
| EPS | -3.71 | -7.83 | 14.74 | -29.61 | -56.69 |
| Diluted EPS | -3.71 | -7.83 | 14.74 | -29.61 | -56.69 |
| Weighted Average OS | 11.25M | 2.23M | 1.27M | 930,352 | 806,837 |
| EBITDA | -$35.9M | -$13.12M | $18.69M | -$30.5M | -$43.37M |
| EBITDA Margin | - | - | - | -117.7% | -138.0% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $57.98M | $83.6M | $7.35M | $16.05M | $117.76M | $70.44M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $57.98M | $83.6M | $7.35M | $16.05M | $117.76M | $70.44M |
| Accounts Receivable | $0 | $2.34M | $0 | $0 | $3.31M | $1.71M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $1M | $2.3M | $198K | $471K | $6.55M | $3.58M |
| Total Current Assets | $58.99M | $88.23M | $7.55M | $16.52M | $127.63M | $75.72M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $572K | $0 | $0 | $0 | $23.03M | $25.98M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $2.9M | $3.31M |
| Total Long-Term Assets | $572K | $0 | $0 | $0 | $25.93M | $29.29M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $59.56M | $88.23M | $7.55M | $16.52M | $153.56M | $105.01M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $4.59M | $4.59M | $936K | $3.18M | $8.61M | $1.79M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $1.05M | $1.03M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $25.12M | $12.63M |
| Other Current Liabilities | $4.82M | $6.24M | $344K | $921K | $12.21M | $3.94M |
| Total Current Liabilities | $11.34M | $12.04M | $2.36M | $5.78M | $50.56M | $22.14M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $431K | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $38.4M | $35.9M |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $19.8M | $13.59M | $9.07M | $33.92M | $0 | $6K |
| Total Long-Term Liabilities | $20.23M | $13.59M | $9.07M | $33.92M | $52.24M | $51.84M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $31.58M | $25.63M | $11.43M | $39.7M | $102.81M | $73.98M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $70.6M | $70.6M | $0 | $0 |
| Common Stock | $12K | $11K | $0 | $0 | $72K | $56K |
| Retained Earnings | -$135.45M | -$93.73M | -$76.3M | -$94.99M | -$257.14M | -$211.41M |
| Comprehensive Income & Other | $83K | $3K | $0 | $0 | $829K | -$295K |
| Other Stockholders' Equity | $163.42M | $156.33M | $72.42M | $71.82M | $307.83M | $242.38M |
| Total Equity | $27.98M | $62.61M | -$3.88M | -$23.17M | $50.76M | $31.03M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $59.56M | $88.23M | $7.55M | $16.52M | $153.56M | $105.01M |
| Supplementary Data | ||||||
| Total Debt | $633K | $0 | $0 | $0 | $14.89M | $16.96M |
| Net Debt | -$57.35M | -$83.6M | -$7.35M | -$16.05M | -$102.87M | -$53.47M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$41.72M | -$17.43M | $18.69M | -$27.55M | -$45.74M | -$37.23M |
| Depreciation & Amortization | $0 | $0 | $0 | $2.78M | $2.37M | $2.13M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $164K |
| Stock-Based Compensation | $6.4M | $830K | $603K | $427K | $0 | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $2.49M | -$1.98M | $0 | $0 | -$1.81M | $5.34M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $1.26M | $2.24M | -$2.25M | $1.98M | $7.05M | -$4.35M |
| Other Working Capital | $64K | -$453K | -$904K | -$359K | $25.29M | -$17.37M |
| Total Working Capital Change | $3.82M | -$193K | -$3.15M | $1.62M | $30.52M | -$16.38M |
| Other Non-Cash Items | $6.49M | $5.96M | -$29.85M | $7.88M | $5.18M | $5.42M |
| Net Cash from Operating | -$25.01M | -$10.84M | -$13.7M | -$14.84M | -$7.66M | -$45.9M |
| Investing Activities | ||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | -$949K | -$2.73M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | -$41.5M |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $83.44M |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | $0 | -$949K | $39.21M |
| Financing Activities | ||||||
| Debt Repaid | - | -$78.43M | - | - | - | - |
| Common Stock Issuance | $763K | $0 | $0 | $0 | $59.13M | $10.12M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.42M | $8.65M | $5M | $34K | $0 | $0 |
| Net Cash from Financing | -$660K | $87.09M | $5M | $9.57M | $59.13M | $10.12M |
| Forex Effect | $46K | $3K | -$22.58M | $0 | -$3.19M | $4.75M |
| Net Change in Cash | -$25.62M | $76.25M | -$31.29M | -$5.27M | $47.33M | $8.18M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$25.01M | -$10.84M | -$13.7M | -$14.84M | -$7.66M | -$45.9M |
| Capital Expenditure | $0 | $0 | $0 | $0 | -$949K | -$2.73M |
| Free Cash Flow | -$25.01M | -$10.84M | -$13.7M | -$14.84M | -$8.61M | -$48.62M |
| Cash at Beginning | $83.6M | $7.35M | $38.63M | $21.33M | $70.44M | $62.26M |
| Cash at End | $57.98M | $83.6M | $7.35M | $16.05M | $117.76M | $70.44M |